scholarly journals Urinary fatty acid binding protein 3 (uFABP3) is a potential biomarker for peripheral arterial disease

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Abdelrahman Zamzam ◽  
Muzammil H. Syed ◽  
John Harlock ◽  
John Eikelboom ◽  
Krishna K. Singh ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Arterial Disease ◽  
Prior History ◽  
P Value ◽  
Fatty Acid Binding ◽  
Coronary Arterial Disease ◽  
Acid Binding Protein ◽  
Potential Biomarker

AbstractPlasma levels of fatty acid binding protein 3 (pFABP3) are elevated in patients with peripheral artery disease (PAD). Since the kidney filters FABP3 from circulation, we investigated whether urinary fatty acid binding protein 3 (uFABP3) is associated with PAD, and also explored its potential as a diagnostic biomarker for this disease state. A total of 130 patients were recruited from outpatient clinics at St. Michael’s Hospital, comprising of 65 patients with PAD and 65 patients without PAD (non-PAD). Levels of uFABP3 normalized for urine creatinine (uFABP3/uCr) were 1.7-folds higher in patients with PAD [median (IQR) 4.41 (2.79–8.08)] compared with non-PAD controls [median (IQR) 2.49 (1.78–3.12), p-value = 0.001]. Subgroup analysis demonstrated no significant effect of cardiovascular risk factors (age, sex, hypertension, hypercholesteremia, diabetes and smoking) on uFABP3/uCr in both PAD and non-PAD patients. Spearmen correlation studies demonstrated a significant negative correlation between uFABP3/uCr and ABI (ρ = − 0.436; p-value = 0.001). Regression analysis demonstrated that uFABP3/Cr levels were associated with PAD independently of age, sex, hypercholesterolemia, smoking, prior history of coronary arterial disease and Estimated Glomerular Filtration rate (eGFR) [odds ratio: 2.34 (95% confidence interval: 1.47–3.75) p-value < 0.001]. Lastly, receiver operator curve (ROC) analysis demonstrated unadjusted area under the curve (AUC) for uFABP3/Cr of 0.79, which improved to 0.86 after adjusting for eGFR, age, hypercholesteremia, smoking and diabetes. In conclusion, our results demonstrate a strong association between uFABP3/Cr and PAD and suggest the potential of uFABP3/Cr in identifying patients with PAD.

scholarly journals Fatty Acid Binding Protein 4—A Circulating Protein Associated with Peripheral Arterial Disease in Diabetic Patients

2020 ◽  
Vol 9 (9) ◽  
pp. 2843 ◽  
Author(s):  
Abdelrahman Zamzam ◽  
Muzammil H. Syed ◽  
Elisa Greco ◽  
Mark Wheatcroft ◽  
Shubha Jain ◽  
...  
Keyword(s):  
Fatty Acid Binding Protein ◽  
Arterial Disease ◽  
Prior History ◽  
P Value ◽  
Diabetic Patients ◽  
Fatty Acid Binding ◽  
Coronary Arterial Disease ◽  
Acid Binding Protein ◽  
History Of ◽  
Peripheral Arterial

Diabetic patients with peripheral arterial disease (PAD) often suffer from poor clinical outcomes such as limb-loss. Fatty acid binding protein 4 (FABP4) is mainly expressed by adipocytes and is known to play a significant role in the development of atherosclerosis. In this study, we sought to investigate whether FABP4 is associated with PAD in patients with type 2 diabetes mellitus (DM). FABP4 plasma levels were studied in 119 diabetic patients with PAD (DM-PAD) and 49 diabetic patients without PAD (DM-noPAD) presenting to St. Michael’s Hospital between October 2017 and September 2018. Levels of FABP4 in DM-PAD patients (23.34 ± 15.27 ng/mL) were found to be over two-fold higher than the levels in DM-noPAD patients (10.3 ± 7.59 ng/mL). Regression analysis demonstrated a significant association between FABP4 levels and DM-PAD after adjusting for age, sex, prior history of coronary arterial disease and white blood cells count (OR, 2.77; 95% CI, 1.81–4.31; p-value = 0.001). Relative to DM-noPAD controls, plasma FABP4 levels in DM-PAD patients were noted to be inversely correlated with the ankle brachial index (ABI; r= −0.374, p-value < 0.001). The diagnostic ability of FABP4 was investigated using receiver operator curves (ROC) and area under the curve (AUC) analysis. FABP4 had an AUC of 0.79, which improved to 0.86 after adjusting for age, sex and prior history of coronary arterial disease. This raises a possibility of utilizing FABP4 as a biomarker for diagnosing PAD in diabetic patients.

scholarly journals Fatty acid binding protein 4 (FABP4) as a potential biomarker reflecting myocardial lipid storage in type 2 diabetes

Metabolism ◽  
2019 ◽  
Vol 96 ◽  
pp. 12-21 ◽  
Author(s):  
Ricardo Rodríguez-Calvo ◽  
Josefa Girona ◽  
Marina Rodríguez ◽  
Sara Samino ◽  
Emma Barroso ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Fatty Acid ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Lipid Storage ◽  
Fatty Acid Binding ◽  
Acid Binding Protein ◽  
Potential Biomarker

scholarly journals Serum Fatty Acid Binding Protein 5 (FABP5) as a Potential Biomarker of Inflammation in Psoriasis.

2020 ◽  
Author(s):  
Dorota Kozłowska ◽  
Hanna Myśliwiec ◽  
Ewa Harasim-Symbor ◽  
Anna Milewska ◽  
Adrian Chabowski ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Total Serum ◽  
Gas Liquid Chromatography ◽  
Metabolic Disturbances ◽  
Fatty Acid Binding ◽  
Acid Binding Protein ◽  
Potential Biomarker ◽  
Narrowband Uvb

Abstract Background: Psoriasis is an immune-mediated chronic inflammatory disease with cardiometabolic comorbidities. Fatty acid binding protein 5 (FABP5) is elevated in human psoriatic keratinocytes and could be potentially involved in systemic metabolic disturbances. The aim of the study was to evaluate serum FABP5 in psoriatic patients, to assess the relationship between FABP5 and the duration, severity of the disease, inflammatory and metabolic markers and influence of treatment with narrowband UVB (NB-UVB). Methods: A total of 74 patients with active plaque-type psoriasis and 30 healthy controls were enrolled in the study. Thirty patients were treated with NB-UVB. Patients were divided into subgroups based on their BMI (Body Mass Index) and disease severity measured by PASI (Psoriasis Area and Severity Index). The serum concentrations of FABP5 were measured using commercially available Human FABP5 ELISA kit. Total serum fatty acids content and composition was measured by gas–liquid chromatography and flame ionization detector after direct in situ transesterificationResults: Serum FABP5 levels in psoriatic patients (both obese and non-obese) were higher versus control group (p<0.001). FABP5 in patients with PASI >20 was higher compared to the mild group (PASI <10) (p<0.001) and serum FABP5 correlated positively with PASI score (r=0.41, p<0.001). We found positive correlation between FABP5 and basic inflammation indices: C-reactive protein, white blood cell count and the platelet count. Decrease of PASI after NB-UVB treatment (p<0.001) was observed and accompanied by decrease of the serum FABP5 (p=0.007). Conclusion: FABP5 is a potential marker of psoriasis, its severity and clinical outcome after therapy with NB-UVB. FABP5 may reflect metabolic disturbances and might be the potential missing link between psoriasis and metabolic disturbances.

scholarly journals Fatty acid binding protein 3 is associated with peripheral arterial disease

2020 ◽  
Vol 1 ◽  
pp. 168-175 ◽  
Author(s):  
Muzammil H. Syed ◽  
Abdelrahman Zamzam ◽  
Hamzah Khan ◽  
Krishna Singh ◽  
Thomas L. Forbes ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Peripheral Arterial Disease ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Arterial Disease ◽  
Fatty Acid Binding ◽  
Acid Binding Protein ◽  
Peripheral Arterial

scholarly journals Serum Fatty Acid Binding protein 5 (FABP5) as a Potential Biomarker of Inflammation in Psoriasis.

2020 ◽  
Author(s):  
Dorota Kozłowska ◽  
Hanna Myśliwiec ◽  
Ewa Harasim-Symbor ◽  
Anna Justyna Milewska ◽  
Adrian Chabowski ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Total Serum ◽  
Enzyme Linked Immunosorbent Assay ◽  
Gas Liquid Chromatography ◽  
Metabolic Disturbances ◽  
Fatty Acid Binding ◽  
Acid Binding Protein ◽  
Potential Biomarker

Abstract Background: Psoriasis is an immune-mediated chronic inflammatory disease with cardiometabolic comorbidities. Fatty acid binding protein 5 (FABP5) is elevated in human psoriatic keratinocytes and could be potentially involved in systemic metabolic disturbances. The aim of the study was to evaluate serum FABP5 in psoriatic patients, to assess the relationship between FABP5 and the duration, severity of the disease, inflammatory and metabolic markers and influence of treatment with narrowband - ultraviolet B (NB-UVB). Methods: Seventy four patients with active plaque-type psoriasis and 30 healthy controls were enrolled in the study. Thirty patients were treated with NB-UVB. Patients were divided into subgroups based on their disease severity measured by Psoriasis Area and Severity Index (PASI) and Body Mass Index (BMI). The serum concentrations of FABP5 were measured using commercially available Human FABP5 Enzyme-Linked Immunosorbent Assay kit. Total serum fatty acids content and composition was measured by gas–liquid chromatography. Results: Serum FABP5 levels in psoriatic patients (both obese and non-obese) were higher versus control group (P <0.001). FABP5 in patients with PASI >20 was higher compared to the mild group (PASI <10) (P <0.001) and serum FABP5 correlated positively with PASI score (r=0.41, P <0.001). There was also positive correlation between FABP5 and basic inflammation indices: C-reactive protein, white blood cell count and the platelet count. Decrease of PASI after NB-UVB treatment (P <0.001) was observed and accompanied by decrease of the serum FABP5 (P=0.007). Conclusion: FABP5 is a potential marker of psoriasis, its severity and clinical outcome after therapy with NB-UVB. FABP5 may reflect metabolic disturbances and might be the missing link between psoriasis and metabolic disturbances.

scholarly journals Serum fatty acid binding protein 5 (FABP5) as a potential biomarker of inflammation in psoriasis

2021 ◽  
Author(s):  
Dorota Kozłowska ◽  
Hanna Myśliwiec ◽  
Ewa Harasim-Symbor ◽  
Anna Justyna Milewska ◽  
Adrian Chabowski ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Gas Liquid Chromatography ◽  
Metabolic Disturbances ◽  
Fatty Acid Binding ◽  
Acid Binding Protein ◽  
Potential Biomarker

AbstractFatty acid binding protein 5 (FABP5) is elevated in psoriatic keratinocytes and could be involved in systemic metabolic disturbances in psoriasis. The aim of the study was to evaluate serum FABP5 in obese and non-obese psoriatic patients, to assess the relationship between FABP5 and the duration, severity of the disease, inflammatory and metabolic markers and influence of treatment with narrowband—ultraviolet B (NB-UVB). Seventy-four patients (30 treated with NB-UVB) with psoriasis were enrolled in the study. The serum concentrations of FABP5 were measured using Human FABP5 Enzyme-Linked Immunosorbent Assay kit. Serum fatty acids were measured by gas–liquid chromatography. Serum FABP5 levels in psoriatic patients were higher versus control group (P < 0.001). FABP5 in patients with PASI > 20 was higher compared to the mild group (PASI < 10) (P < 0.001) and serum FABP5 correlated positively with PASI score (r = 0.41, P < 0.001). There was also positive correlation between FABP5 and basic inflammation indices. Decrease of PASI after NB-UVB treatment (P < 0.001) was observed and accompanied by decrease of the serum FABP5 (P = 0.007). FABP5 is a potential marker of psoriasis, its severity and clinical outcome after therapy with NB-UVB. FABP5 may reflect metabolic disturbances in psoriatic patients.

scholarly journals Increased Urinary Liver-Type Fatty Acid-Binding Protein Level Predicts Major Adverse Cardiovascular Events in Patients With Hypertension

2020 ◽  
Vol 33 (7) ◽  
pp. 604-609
Author(s):  
Yousaku Okubo ◽  
Yukiko Nakano ◽  
Takehito Tokuyama ◽  
Naoya Hironobe ◽  
Sho Okamura ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Cardiovascular Events ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
End Points ◽  
Fatty Acid Binding ◽  
Acid Binding Protein ◽  
End Point ◽  
Potential Biomarker

Abstract Background Urinary liver-type fatty acid-binding protein (L-FABP) has been known as a potential biomarker for acute kidney injury. It has also been suggested to have an effective predictive value for cardiovascular mortality in patients with diabetes or critically ill condition. Therefore, this study aimed to examine the ability of urinary L-FABP in predicting mid-term cardiovascular morbidity and mortality in patients with hypertension. Methods Urinary L-FABP levels in stable outpatients without diabetes who were treated with antihypertensive drugs were measured, and a 5-year follow-up was planned. The primary end-point was a combination of acute heart failure requiring hospitalization, myocardial infarction, stroke, and cardiovascular death. The secondary end-point was kidney disease progression defined as a relative decline in the estimated glomerular filtration rate of ≥30% from the baseline. Results A total of 197 patients were recruited. Primary and secondary end-points occurred in 24 (12.2%) and 42 (21.3%) patients, respectively, during a median follow-up of 5.7 years. Patients with urinary L-FABP levels higher than the upper limit (8.4 µg/g creatinine) were more likely to reach the primary (30.43% vs. 9.77%; P = 0.003) and secondary end-points (56.52% vs. 16.67%; P &lt; 0.001) than those with urinary L-FABP levels within the normal limits. Urinary L-FABP level was independently associated with both primary (hazard ratio (HR) 1.21; P = 0.03) and secondary end-points (HR 1.19; P = 0.02). Conclusions This study demonstrated that increased urinary L-FABP levels may predict adverse cardiovascular events and renal dysfunction progression even among stable nondiabetic patients with hypertension.

Sign in / Sign up

Export Citation Format

Share Document